BioStem Technologies Announces Nasdaq Uplisting
Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 — BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on…
-
-
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
Advances progress towards planned Nasdaq uplisting POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the…
-
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BSEM), a leading regenerative medicine company focused on…
-
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
POMPANO BEACH, Fla., June 10, 2026 — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
-
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
The new independent directors strengthen the Company’s board as seasoned executives bring deep expertise in life sciences commercialization, healthcare administration, and investment management. POMPANO BEACH, Fla., June 09, 2026 (GLOBE…
-
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor Strengthening balance sheet on path to Nasdaq uplisting
POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
-
BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent
BioStem Technologies Expands Global Placental Allograft Patent Portfolio Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) — BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived…
-
BioStem Technologies Reports First Quarter 2026 Financial Results
POMPANO BEACH, Fla., May 14, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
-
BioStem Technologies to Present at the 16th Annual LD Micro Invitational
POMPANO BEACH, Fla., May 12, 2026 — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced…
-
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) — BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products,…